Arovella Therapeutics Limited (ALA.AX)
AUD 0.09
(4.55%)
AUD 0.09
(4.55%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -8.74 Million AUD | 14.1% |
| 2023 | -10.18 Million AUD | -18.11% |
| 2022 | -8.62 Million AUD | -70.79% |
| 2021 | -5.04 Million AUD | 49.24% |
| 2020 | -9.94 Million AUD | -27.57% |
| 2019 | -7.79 Million AUD | -42.79% |
| 2018 | -5.45 Million AUD | -340.87% |
| 2017 | -1.23 Million AUD | 44.49% |
| 2016 | -2.23 Million AUD | 33.75% |
| 2015 | -3.36 Million AUD | -64.11% |
| 2014 | -2.05 Million AUD | -23.04% |
| 2013 | -1.66 Million AUD | 63.71% |
| 2012 | -4.59 Million AUD | -1.91% |
| 2011 | -4.5 Million AUD | 7.15% |
| 2010 | -4.85 Million AUD | -61.73% |
| 2009 | -3 Million AUD | 67.36% |
| 2008 | -9.19 Million AUD | -418.81% |
| 2007 | -1.77 Million AUD | -566.64% |
| 2006 | -265.99 Thousand AUD | 86.21% |
| 2005 | -1.92 Million AUD | 0.0% |
| 2004 | - AUD | 100.0% |
| 2003 | -1.06 Million AUD | -41.8% |
| 2002 | -751 Thousand AUD | -848.39% |
| 2001 | -79.18 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.94 Million AUD | -100.0% |
| 2024 Q3 | -2.4 Million AUD | 39.17% |
| 2024 FY | -8.74 Million AUD | 14.1% |
| 2024 Q4 | -2.4 Million AUD | 0.0% |
| 2024 Q1 | -1.97 Million AUD | 68.6% |
| 2023 Q3 | -3.14 Million AUD | 19.44% |
| 2023 Q2 | -3.89 Million AUD | -100.0% |
| 2023 Q1 | -1.94 Million AUD | 58.26% |
| 2023 FY | -10.18 Million AUD | -18.11% |
| 2023 Q4 | -6.28 Million AUD | -100.0% |
| 2022 Q3 | -2.33 Million AUD | 40.88% |
| 2022 Q4 | -4.67 Million AUD | -100.0% |
| 2022 FY | -8.62 Million AUD | -70.79% |
| 2022 Q1 | -1.97 Million AUD | 40.15% |
| 2022 Q2 | -3.94 Million AUD | -100.0% |
| 2021 Q2 | -1.74 Million AUD | -100.0% |
| 2021 Q3 | -1.65 Million AUD | 5.57% |
| 2021 Q4 | -3.3 Million AUD | -100.0% |
| 2021 FY | -5.04 Million AUD | 49.24% |
| 2021 Q1 | -873.68 Thousand AUD | 60.93% |
| 2020 FY | -9.94 Million AUD | -27.57% |
| 2020 Q2 | -7.69 Million AUD | -100.0% |
| 2020 Q1 | -3.84 Million AUD | 44.41% |
| 2020 Q3 | -1.11 Million AUD | 85.48% |
| 2020 Q4 | -2.23 Million AUD | -100.0% |
| 2019 Q3 | -3.46 Million AUD | -695.67% |
| 2019 Q2 | -435.15 Thousand AUD | 0.0% |
| 2019 Q1 | -435.15 Thousand AUD | 77.14% |
| 2019 Q4 | -6.92 Million AUD | -100.0% |
| 2019 FY | -7.79 Million AUD | -42.79% |
| 2018 Q4 | -1.9 Million AUD | 0.0% |
| 2018 Q2 | -1.11 Million AUD | 0.0% |
| 2018 FY | -5.45 Million AUD | -340.87% |
| 2018 Q1 | -1.11 Million AUD | -336.38% |
| 2018 Q3 | -1.9 Million AUD | -70.98% |
| 2017 Q4 | -255.1 Thousand AUD | -58.56% |
| 2017 FY | -1.23 Million AUD | 44.49% |
| 2017 Q3 | -160.88 Thousand AUD | 65.83% |
| 2017 Q2 | -470.82 Thousand AUD | 0.0% |
| 2017 Q1 | -470.82 Thousand AUD | -98.08% |
| 2016 Q1 | -905.71 Thousand AUD | -27.36% |
| 2016 FY | -2.23 Million AUD | 33.75% |
| 2016 Q4 | -237.69 Thousand AUD | 0.0% |
| 2016 Q2 | -905.71 Thousand AUD | 0.0% |
| 2016 Q3 | -237.69 Thousand AUD | 73.76% |
| 2015 FY | -3.36 Million AUD | -64.11% |
| 2015 Q4 | -711.16 Thousand AUD | 0.0% |
| 2015 Q3 | -711.16 Thousand AUD | 26.87% |
| 2015 Q2 | -972.42 Thousand AUD | 0.0% |
| 2015 Q1 | -972.42 Thousand AUD | -13.08% |
| 2014 Q2 | -165.92 Thousand AUD | 0.0% |
| 2014 Q1 | -165.92 Thousand AUD | 52.68% |
| 2014 FY | -2.05 Million AUD | -23.04% |
| 2014 Q4 | -859.97 Thousand AUD | 0.0% |
| 2014 Q3 | -859.97 Thousand AUD | -418.3% |
| 2013 Q1 | -483.11 Thousand AUD | 0.0% |
| 2013 Q3 | -350.64 Thousand AUD | 27.42% |
| 2013 Q4 | -350.64 Thousand AUD | 0.0% |
| 2013 FY | -1.66 Million AUD | 63.71% |
| 2013 Q2 | -483.11 Thousand AUD | 0.0% |
| 2012 FY | -4.59 Million AUD | -1.91% |
| 2011 FY | -4.5 Million AUD | 7.15% |
| 2010 FY | -4.85 Million AUD | -61.73% |
| 2009 FY | -3 Million AUD | 67.36% |
| 2008 FY | -9.19 Million AUD | -418.81% |
| 2007 FY | -1.77 Million AUD | -566.64% |
| 2006 FY | -265.99 Thousand AUD | 86.21% |
| 2005 FY | -1.92 Million AUD | 0.0% |
| 2004 FY | - AUD | 100.0% |
| 2003 FY | -1.06 Million AUD | -41.8% |
| 2002 FY | -751 Thousand AUD | -848.39% |
| 2001 FY | -79.18 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -62.527% |
| Acrux Limited | -5.8 Million AUD | -50.794% |
| Actinogen Medical Limited | -13.04 Million AUD | 32.951% |
| AnteoTech Limited | -8.88 Million AUD | 1.514% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -59.614% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -502.659% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 54.265% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -94.207% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -154.5% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -263.03% |
| Biome Australia Limited | -1.67 Million AUD | -423.651% |
| Biotron Limited | -3.43 Million AUD | -154.502% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 36.941% |
| BTC Health Limited | 1.05 Million AUD | 928.783% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 30.198% |
| CSL Limited | 2.64 Billion AUD | 100.331% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 79.336% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 124.542% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 10.248% |
| Dimerix Limited | -17.07 Million AUD | 48.779% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 225.58% |
| Hexima Limited | -933.87 Thousand AUD | -836.534% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -205.344% |
| Immuron Limited | -6.93 Million AUD | -26.079% |
| Immutep Limited | -39.89 Million AUD | 78.078% |
| Imugene Limited | -149.68 Million AUD | 94.157% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -432.707% |
| Memphasys Limited | -4.44 Million AUD | -96.893% |
| Nanollose Limited | -1.15 Million AUD | -656.216% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 105.568% |
| Noxopharm Limited | -3.57 Million AUD | -144.431% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 2797.645% |
| Nyrada Inc. | -1.38 Million AUD | -530.924% |
| Orthocell Limited | -7.18 Million AUD | -21.795% |
| PharmAust Limited | -9.03 Million AUD | 3.17% |
| Patrys Limited | -3.53 Million AUD | -147.122% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 85.089% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -37.166% |
| Prescient Therapeutics Limited | -8.23 Million AUD | -6.166% |
| PYC Therapeutics Limited | -37.72 Million AUD | 76.817% |
| Race Oncology Limited | -13.81 Million AUD | 36.712% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 81.76% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 50.48% |
| Starpharma Holdings Limited | -8.16 Million AUD | -7.116% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 267.838% |
| Tissue Repair Ltd | -4.13 Million AUD | -111.354% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 76.083% |